Central signaling
MC4R is expressed in brain regions associated with motivation, appetite, and sexual response.
P—15 • Clinically established profile
PT-141
A concise educational overview of a clinically established melanocortin-receptor agonist studied for centrally mediated sexual-desire signaling.
Name
PT-141
Also known as bremelanotide; the FDA-approved product is Vyleesi
- Scientific classification
- Synthetic cyclic heptapeptide and melanocortin-receptor agonist derived from alpha-melanocyte-stimulating hormone research
- Library family
- Neuroactive
- Research status
- Clinically established for a specific indication, with continuing research into melanocortin signaling and sexual-response neurobiology
- Regulatory status
- FDA approved as Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder; the indication does not include men, postmenopausal women, or general sexual-performance enhancement
Compound overview
A centrally acting melanocortin peptide with an established clinical application.
PT-141 is a centrally acting peptide that activates melanocortin receptors involved in neural signaling.
Unlike treatments acting primarily through blood-vessel pathways or directly replacing reproductive hormones, bremelanotide is studied for its influence on brain pathways associated with sexual desire and response.
Mechanism under study
Central melanocortin-receptor signaling
Bremelanotide activates several melanocortin receptor subtypes. MC4R is considered the most relevant at therapeutic exposure, although the exact mechanism through which it improves HSDD symptoms has not been completely established.
Excitatory pathways
Preclinical research suggests melanocortin signaling may influence hypothalamic pathways and dopamine release associated with sexual desire.
Broader receptor activity
Interaction with additional melanocortin receptors contributes to bremelanotide’s wider pharmacologic and safety profile.
Its clinical effects are understood as centrally mediated rather than simply vascular.
Current research areas
Questions under investigation
- Acquired, generalized HSDD
- Central regulation of sexual desire
- MC4R and melanocortin-receptor signaling
- Dopamine and hypothalamic response pathways
- Receptor-selective analogues and additional populations
Evidence summary
Evidence-supported neurobehavioral outcomes
- Improved sexual desire: Two Phase 3 trials reported statistically significant changes in validated measures of sexual desire.
- Reduced desire-related distress: Participants reported reductions in distress associated with low sexual desire.
- Consistent subgroup findings: Benefits were observed across numerous studied age, weight, BMI, testosterone, and hormonal-contraceptive subgroups.
- Patient-reported experience: Follow-up research described changes in desire, physical arousal, and the perceived quality of sexual experiences.
- Nonhormonal central pathway: Bremelanotide provides an established example of addressing sexual-desire biology through neural melanocortin signaling rather than hormone replacement.
These findings provide strong clinical support within the defined FDA-approved population and create a foundation for continued neuroendocrine and sexual-health research.
Educational notice
Education, not usage guidance.
This profile is provided for scientific education only. It is not medical advice, prescribing guidance, dosing information, or instructions for PT-141 or bremelanotide use. FDA labeling identifies clinically important considerations including temporary increases in blood pressure, reductions in heart rate, nausea, flushing, headache, injection-site reactions, and possible focal hyperpigmentation. The approved product is contraindicated in people with uncontrolled hypertension or known cardiovascular disease and can affect the absorption of certain oral medications.
Key scientific referencesComing soon
A curated primary-source reference list will be added during the next educational expansion.